The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, predict progression, and assess the effectiveness of new treatments.

Past AlzForum Coverage:

1. Clinical Trials on Alzheimer's Disease 2012
   • CTAD: Turning the Ship Around Toward Early Trials
   • CTAD: New Data on Sola, Bapi, Spark Theragnostics Debate
   • CTAD: Regulatory Science Gains Prominence in AD Research
   • CTAD: Adaptive Antibody Trial to Try Bayesian Statistics
   • CTAD: ApoE Carriers Sought for Trial of NSAID Derivative
   • CTAD: EEG Gains Luster as More Trials Incorporate Biomarkers
   • CTAD: AD Treatment Might Not Lower Healthcare Costs
2. Clinical Trials on Alzheimer's Disease 2011
   • Nutrient Formulation Appears to Grease Memory Function
   • Door Slams on RAGE
   • Whence and Where To: History and Future of AD Therapy Trials
   • Clinical Trials: Making “Protocols From Hell” Less Burdensome
   • EEG: Coming in From the Margins of Alzheimer’s Research?
   • EEG: Old Method to Lend New Help in AD Drug Development?
   • Reeling In Biomarker Data in Young Carriers, API Rocks Staging Boat
   • Time Is Ripe for Clinical Trials in Frontotemporal Degeneration
   • Pieces Move Into Place to Stage Frontotemporal Trials
3. Clinical Trials on Alzheimer's Disease 2010
   • Toulouse: Experimental Drug Sensitizes Receptor, Boosts Cognition